Literature DB >> 12400062

Fetal akinesia deformation sequence: a study of 30 consecutive in utero diagnoses.

Ingrid Witters1, Philippe Moerman, Jean-Pierre Fryns.   

Abstract

The etiology of the fetal akinesia deformation sequence (FADS) is heterogeneous and can be the result of neurogenic and myopathic disorders, restrictive dermopathy, teratogen exposure, and intrauterine constraint. We present the prenatal and fetopathological findings in a consecutive series of 30 affected fetuses with normal chromosomal results. According to the in utero time of onset of the fetal akinesia, the severity of the phenotype varied from a severe, generalized FADS in the early-onset group to milder defects, as isolated distal arthrogryposis in the late-onset group. No more than 10% (3/30) were diagnosed in the first trimester of pregnancy and all presented a severe phenotype. Twenty-seven of the thirty (90%) were diagnosed after the first trimester, with a severe FADS in 15/27 and a milder phenotype of distal arthrogryposis in 12/27. In all 30 patients, extensive neuropathological studies (brain, spinal cord, and muscles) were performed. In 16 patients (53%) a specific diagnosis could be made (central nervous system abnormalities 9/16; spinal cord 1/16; primary myopathy 3/16; syndromic 3/16). In 10 others (33%), pathological neuromuscular findings were present but no definitive diagnosis was established. In 4 patients (13%), neuromuscular findings were normal, and the etiology of the FADS remained unexplained. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12400062     DOI: 10.1002/ajmg.10698

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  8 in total

Review 1.  Fetal MRI: techniques and protocols.

Authors:  Daniela Prayer; Peter Christian Brugger; Lucas Prayer
Journal:  Pediatr Radiol       Date:  2004-07-28

2.  Mutations in FLVCR2 are associated with proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome (Fowler syndrome).

Authors:  Esther Meyer; Christopher Ricketts; Neil V Morgan; Mark R Morris; Shanaz Pasha; Louise J Tee; Fatimah Rahman; Anne Bazin; Bettina Bessières; Pierre Déchelotte; Mohamed T Yacoubi; Mudher Al-Adnani; Tamas Marton; David Tannahill; Richard C Trembath; Catherine Fallet-Bianco; Phillip Cox; Denise Williams; Eamonn R Maher
Journal:  Am J Hum Genet       Date:  2010-03-04       Impact factor: 11.025

3.  Diagnosing arthrogryposis multiplex congenita: a review.

Authors:  Emmanouil Kalampokas; Theodoros Kalampokas; Chrisostomos Sofoudis; Efthymios Deligeoroglou; Dimitrios Botsis
Journal:  ISRN Obstet Gynecol       Date:  2012-09-23

Review 4.  Investigation of normal organ development with fetal MRI.

Authors:  Daniela Prayer; Peter C Brugger
Journal:  Eur Radiol       Date:  2007-03-07       Impact factor: 7.034

5.  Arthrogryposis: an update on clinical aspects, etiology, and treatment strategies.

Authors:  Bartłomiej Kowalczyk; Jarosław Feluś
Journal:  Arch Med Sci       Date:  2016-02-02       Impact factor: 3.318

6.  Fetal akinesia deformation sequence, arthrogryposis multiplex congenita, and bilateral clubfeet: Is motor assessment of additional value for in utero diagnosis? A 10-year cohort study.

Authors:  Jill K Tjon; Gita M Tan-Sindhunata; Marianna Bugiani; Melinda M Witbreuk; Johannes A van der Sluijs; Marjan M Weiss; Laura A van de Pol; Mirjam M van Weissenbruch; Bloeme J van der Knoop; Johanna I de Vries
Journal:  Prenat Diagn       Date:  2019-02-07       Impact factor: 3.050

Review 7.  Computation of Fetal Kicking in Various Fetal Health Examinations: A Systematic Review.

Authors:  Yuwei Liu; Rongrong Xuan; Yuhuan He; Feng Ren; Yaodong Gu
Journal:  Int J Environ Res Public Health       Date:  2022-04-05       Impact factor: 3.390

Review 8.  Management of arthrofibrosis in neuromuscular disorders: a review.

Authors:  Edith Martinez-Lozano; Indeevar Beeram; Diana Yeritsyan; Mark W Grinstaff; Brian D Snyder; Ara Nazarian; Edward K Rodriguez
Journal:  BMC Musculoskelet Disord       Date:  2022-07-29       Impact factor: 2.562

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.